The patent for semaglutide, the active ingredient in the weight-loss drugs Wegovy and Ozempic, expired in India on Friday, March 20, 2026, opening the door for domestic pharmaceutical companies to manufacture and distribute cheaper generic versions of the medication.
The expiration of the patent, held by Danish pharmaceutical giant Novo Nordisk, is expected to significantly lower the cost of semaglutide in India, potentially expanding access to a drug that has, until now, been largely confined to affluent patients. Investment bank Jefferies has described the situation as a potential “magic-pill moment” for the Indian market, forecasting a domestic market value of up to $1 billion with appropriate pricing and adoption rates.
Semaglutide, originally developed as a treatment for type 2 diabetes, has gained prominence for its effectiveness in promoting weight loss by mimicking a hormone that regulates appetite and blood sugar. The drugs Wegovy and Ozempic, both utilizing semaglutide, have seen substantial demand globally.
Analysts anticipate a rapid influx of competition, with around 50 branded semaglutide generics expected to enter the Indian market within months. This mirrors a similar pattern observed in 2022 when the patent for the diabetes drug sitagliptin expired, resulting in approximately 30 branded versions appearing within a month and nearly 100 within a year. India’s pharmaceutical industry, currently valued at around $60 billion, is projected to double in size by 2030, largely driven by the production of generic drugs.
Dr. Rahul Baxi, a diabetologist in Mumbai, noted the potential impact of increased affordability. The availability of generic semaglutide could reshape the fight against obesity, not only within India but also potentially in other countries as India’s pharmaceutical manufacturers are known for exporting generics globally.
The move comes as India experiences a growing demand for weight-loss drugs, particularly among its more affluent population. However, the wider availability of affordable generics could broaden access to a larger segment of the population struggling with obesity and related health issues.
Novo Nordisk launched Wegovy in India in 2025, but the expiration of the core ingredient patent marks a significant shift in the market dynamics. The company has not yet commented on its strategy in response to the increased competition.
Leave a Reply